ALDH1A 抑制剂:癌症治疗药物的研究进展
Xianxian Zhao1, Xiang Wen2, Ji Chen3
1Department of Pulmonary and Critical Care Medicine, Molecularly Targeted Research and Development Laboratory, Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, Sichuan, China.
阿尔德脱酶1A (ALDH1A) 抑制剂通过向癌症干细胞,对癌症治疗有希望. 研究重点是开发强大的小分子ALDH1A抑制剂,以克服耐药性并改善临床结果.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 脱酶1A (ALDH1A) 对于癌症干细胞的维护至关重要,驱动瘤发生,进展和治疗抵抗.
- ALDH1A失调与各种癌症,代谢和神经退行性疾病有关.
- 准ALDH1A是一种有前途的治疗策略.
研究的目的:
- 审查ALDH1A抑制剂在癌症治疗中的最新进展.
- 专注于结构优化,结构-活性关系 (SAR) 和小分子ALDH1A抑制剂的作用机制.
- 讨论未来临床转化和克服药物耐药性的方向.
主要方法:
- 关于ALDH1A抑制剂及其在癌症治疗中的应用的文献综述.
- 对小分子ALDH1A抑制剂的结构优化和SAR研究的分析.
- 检查作用机制和药理动力学概况.
主要成果:
- 选择性和强大的ALDH1A抑制剂的开发,包括基于库马林的化合物和二硫衍生物.
- 证明具有显著的抗瘤功效,具有低细胞毒性和有利的药理动力学.
- 强调这些新型抑制剂的临床潜力.
结论:
- ALDH1A 抑制剂代表了对各种癌症的有希望的治疗途径.
- 专注于SAR和机制的进一步开发对于临床翻译至关重要.
- 这些抑制剂提供了克服癌症药物耐药性的潜在策略.
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...


